Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the key treatment goals are to protect the skin barrier, reduce inflammation, and alleviate itch. Topical corticosteroids are often effective for mild AD but have safety, tolerability, and compliance issues. More-effective therapies for topical-refractory and moderate to severe AD are needed. Pfizer’s Eucrisa and Sanofi / Regeneron’s Dupixent were first-to-market in an ongoing AD treatment revolution, with three new topical agents (Japan Tobacco et al.’s Corectim; Otsuka et al.’s Moizerto; Incyte’s Opzelura), one biologic (LEO’s Adtralza), and three JAK inhibitors (AbbVie’s Rinvoq, Eli Lilly’s Olumiant, and Pfizer’s Cibinqo) earning their first approvals in 2020-2021. This report provides a comprehensive analysis of AD patient populations, current disease management, unmet needs, and the clinical and commercial potential of emerging drugs.
QUESTIONS ANSWERED
What are the sizes of the mild, moderate, and severe AD subpopulations? How will they change by 2030? How well are these subpopulations served by current AD therapies?
How have Eucrisa and Dupixent been incorporated into the AD treatment algorithm? What market niches will newer-to-market agents occupy?
What emerging therapies are in development for AD? Of these therapies, which are best poised to achieve commercial success?
What are the greatest unmet treatment needs for AD, and to what degree will therapies in the pipeline address these needs?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Atopic Dermatitis - Key Findings - February 2022 Updated
March 2021
February 2021
Commercial Outlook
Key Findings
Market Share of Drug Classes for Atopic Dermatitis: 2020
Market Share of Drug Classes for Atopic Dermatitis: 2030
Atopic Dermatitis SWOT Analysis
COVID-19: Market Forecast Impact
Market Drivers and Constraints
What Factors Are Driving the Market for Atopic Dermatitis?
What Factors Are Constraining the Market for Atopic Dermatitis?
Drug-Class-Specific Trends
Major-Market Sales of IL-4 / IL-13 Inhibitors: 2020-2030
Major-Market Sales of IL-31 Inhibitors: 2020-2030
Major-Market Sales of JAK Inhibitors: 2020-2030
Major-Market Sales of Topical JAK Inhibitors: 2020-2030
Major-Market Sales of Topical Phosphodiesterase-4 Inhibitors: 2020-2030
Major-Market Sales of Topical Calcineurin Inhibitors: 2020-2030
Forecast
Market Forecast Assumptions
Market Forecast Dashboard
Etiology and Pathophysiology
Disease Overview
Clinical Presentation
Atopic Dermatitis Risk and Protective Factors
Key Risk Factors for Atopic Dermatitis
Protective Factors in Atopic Dermatitis
Social and Economic Burden of Atopic Dermatitis
Atopic Dermatitis Comorbidities
Cutaneous Immunity
The Skin Barrier
Skin Barrier Defects
Key Skin Barrier Proteins Mutated in Atopic Dermatitis
Altered Immune Reactivity and the Skin Microbiome
Key Pathways and Drug Targets
Epidemiology Overview
Key Findings
Key Updates
Epidemiology Populations
Disease Definition
Methods
Sources Used for Prevalence of Atopic Dermatitis
Total Prevalent Cases of Atopic Dermatitis: 2020-2030
Disease Definition
Methods
Sources Used for Severity of 12-Month Total Prevalent Atopic Dermatitis
12-Month Total Prevalent Cases of Atopic Dermatitis by Severity: 2020-2030
Diagnosed Prevalent Cases of Atopic Dermatitis: 2020-2030
Disease Definition
Methods
Sources Used for Severity of Diagnosed 12-Month Prevalent Atopic Dermatitis
Number of Diagnosed 12-Month Total Prevalent Cases of Atopic Dermatitis in the Major Pharmaceutical Markets by Severity: 2020-2030
Drug-Treated Diagnosed Prevalent Cases of Mild Atopic Dermatitis: 2020-2030
Drug-Treated Diagnosed Prevalent Cases of Moderate Atopic Dermatitis: 2020-2030
Drug-Treated Diagnosed Prevalent Cases of Severe Atopic Dermatitis: 2020-2030
Current Treatment
Key Findings
Treatment Goals
Key Endpoints Used in Clinical Trials for Atopic Dermatitis
Key Current Therapies
Overview
Mechanism of Action of Key Current Drugs Classes Used for Atopic Dermatitis
Current Treatments Used for Atopic Dermatitis
Market Events Impacting the Use of Key Current Therapies for Atopic Dermatitis
Clinical Trial Outcomes for Cibinqo
Advantages and Disadvantages of Cibinqo
Key Results From Select Clinical Trials Investigating Cibinqo for the Treatment of Atopic Dermatitis
Ongoing Clinical Development of Cibinqo
Key Ongoing Clinical Trials of Cibinqo in the Treatment of Atopic Dermatitis
Expert Insight: Cibinqo
Rinvoq
Clinical Trial Outcomes for Rinvoq
Advantages and Disadvantages of Rinvoq
Key Results From Select Clinical Trials Investigating Rinvoq for the Treatment of Atopic Dermatitis
Ongoing Clinical Development of Rinvoq
Key Ongoing Clinical Trials of Rinvoq in the Treatment of Atopic Dermatitis
Expert Insight: Rinvoq
Olumiant
Advantages and Disadvantages of Olumiant
Key Results From Select Clinical Trials Investigating Olumiant for the Treatment of Atopic Dermatitis
Ongoing Clinical Development of Olumiant
Key Ongoing Clinical Trials of Olumiant in the Treatment of Atopic Dermatitis
Expert Insight: Olumiant
Advantages and Disadvantages of Eucrisa / Staquis
Key Results From Select Phase III or Phase IV Clinical Trials of Eucrisa / Staquis for the Treatment of Atopic Dermatitis
Ongoing Clinical Development of Eucrisa / Staquis
Key Ongoing Clinical Trials of Eucrisa / Staquis in the Treatment of Atopic Dermatitis
Expert Insight: Eucrisa / Staquis
Moizerto
Advantages and Disadvantages of Moizerto
Key Results From Select Clinical Trials Investigating Moizerto for the Treatment of Atopic Dermatitis
Ongoing Clinical Development of Moizerto
Expert Insight: Moizerto
Adbry / Adtralza
Advantages and Disadvantages of Adbry / Adtralza
Key Results From Select Clinical Trials Investigating Adbry / Adtralza for the Treatment of Atopic Dermatitis
Ongoing Clinical Development of Adbry / Adtralza
Key Ongoing Clinical Trials of Adbry / Adtralza in the Treatment of Atopic Dermatitis
Expert Insight: Adbry / Adtralza
Advantages and Disadvantages of Dupixent
Outcomes From Key Phase III Clinical Trials of Dupixent
Ongoing Clinical Development
Key Ongoing Clinical Trials of Dupixent in the Treatment of Atopic Dermatitis
Expert Insight: Use of Dupixent in the Treatment of Atopic Dermatitis
Advantages and Disadvantages of Opzelura
Clinical Trial Outcomes for Opzelura
Key Results From Select Clinical Trials Investigating Opzelura for the Treatment of Atopic Dermatitis
Ongoing Clinical Development of Opzelura
Key Ongoing Clinical Trials of Opzelura in the Treatment of Atopic Dermatitis
Expert Insight: Opzelura
Corectim
Advantages and Disadvantages of Corectim
Key Results From Clinical Trials Investigating Corectim for the Treatment of Atopic Dermatitis
Ongoing Clinical Development of Corectim
Expert Insight: Corectim
Advantages and Disadvantages of Pimecrolimus
Expert Insight: Use of Pimecrolimus in the Treatment of Atopic Dermatitis
Advantages and Disadvantages of Topical Tacrolimus
Expert Insight: Use of Topical Tacrolimus in the Treatment of Atopic Dermatitis
Potency and Formulations of Corticosteroids Commonly Used in the Treatment of Atopic Dermatitis
Advantages and Disadvantages of Topical Corticosteroids
Expert Insight: Use of Topical Corticosteroids in the Treatment of Atopic Dermatitis
Advantages and Disadvantages of Conventional Oral Immunosuppressants
Expert Insight: Use of Conventional Oral Immunosuppressants in the Treatment of Atopic Dermatitis
Advantages and Disadvantages of Emollients
Expert Insight: Use of Emollients in the Treatment of Atopic Dermatitis
Advantages and Disadvantages of Phototherapy
Expert Insight: Use of Phototherapy in the Treatment of Atopic Dermatitis
Medical Practice
Overview
Factors Influencing Drug Selection in Atopic Dermatitis
Treatment Decision Tree for Atopic Dermatitis: United States
Treatment Decision Tree for Atopic Dermatitis: Europe
Treatment Decision Tree for Atopic Dermatitis: Japan
Unmet Need Overview
Current and Future Attainment of Unmet Needs in Atopic Dermatitis
Top Unmet Needs in Atopic Dermatitis: Current and Future Attainment
Expert Insight: Unmet Need in Atopic Dermatitis
Emerging Therapies
Key Findings
Key Emerging Therapies
Key Therapies in Development for Atopic Dermatitis
Estimated Launch Dates of Key Emerging Therapies for the Treatment of Atopic Dermatitis
Lebrikizumab Profile
Key Ongoing Clinical Trials of Lebrikizumab in the Treatment of Atopic Dermatitis
Analysis of the Clinical Development Program for Lebrikizumab
Expert Insight: Lebrikizumab
Expectations for Launch and Sales Opportunity of Lebrikizumab in Atopic Dermatitis
Key Results From Select Clinical Trials Investigating Nemolizumab for the Treatment of Atopic Dermatitis
Key Ongoing Clinical Trials of Nemolizumab in the Treatment of Atopic Dermatitis
Analysis of the Clinical Development Program for Nemolizumab
Expert Insight: Nemolizumab
Expectations for Launch and Sales Opportunity of Nemolizumab in Atopic Dermatitis
Tradipitant Profile
Key Ongoing Clinical Trials of Tradipitant in the Treatment of Atopic Dermatitis
Analysis of the Clinical Development Program for Tradipitant
Expert Insight: Tradipitant
Expectations for Launch and Sales Opportunity of Tradipitant in Atopic Dermatitis
ARQ-151 Profile
Key Ongoing Clinical Trials of ARQ-151 in the Treatment of Atopic Dermatitis
Analysis of the Clinical Development Program for ARQ-151
Expert Insight: ARQ-151
Expectations for Launch and Sales Opportunity of ARQ-151 in Atopic Dermatitis
Daleuton Profile
Key Ongoing Clinical Trials of Daleuton in the Treatment of Atopic Dermatitis
Analysis of the Clinical Development Program for Daleuton
Expert Insight: Daleuton
Expectations for Launch and Sales Opportunity of Daleuton in Atopic Dermatitis
Tapinarof Profile
Key Ongoing Clinical Trials of Tapinarof in the Treatment of Atopic Dermatitis
Analysis of the Clinical Development Program for Tapinarof
Expert Insight: Tapinarof
Expectations for Launch and Sales Opportunity of Tapinarof in Atopic Dermatitis
Amlitelimab Profile
Analysis of the Clinical Development Program for Amlitelimab
Key Ongoing Clinical Trials of Amlitelimab in the Treatment of Atopic Dermatitis
Expert Insight: Amlitelimab
Expectations for Launch and Sales Opportunity of Amlitelimab in Atopic Dermatitis
Telazorlimab
Telazorlimab Profile
Key Ongoing Clinical Trials of Telazorlimab in the Treatment of Atopic Dermatitis
Analysis of the Clinical Development Program for Telazorlimab
Expert Insights: Telazorlimab
Expectations for Launch and Sales Opportunity of Telazorlimab in Atopic Dermatitis
Early-Phase Pipeline Analysis
Select Compounds in Early-Phase Development for Atopic Dermatitis
Key Discontinuations and Failures in Atopic Dermatitis
Access & Reimbursement Overview
Region-Specific Reimbursement Practices
Key Market Access Considerations in Atopic Dermatitis: United States
General Reimbursement Environment: United States
Key Market Access Considerations in Atopic Dermatitis: EU5
General Reimbursement Environment: EU5
Key Market Access Considerations in Atopic Dermatitis: Japan
General Reimbursement Environment: Japan
Appendix
Atopic Dermatitis Bibliography
Andrew Russell, Ph.D.
Andrew Russell, Ph.D., is a business insights analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. In this role, he authors reports that distill the findings of his research into pharmaceutical markets related to autoimmune disease and bacterial infection. He worked previously in neurodegenerative disease research at Brigham and Women’s Hospital in Boston. He holds a Ph.D. in cellular and molecular biology from Brandeis University.
Misba Farooq
Misba Farooq, B.P.T., M.P.H.,is an associate epidemiologist at Clarivate. Previously, she worked as a hospital-based physiotherapist. She received her master’s degree in public health / social epidemiology from the Tata Institute of Social Sciences and has a bachelor’s degree in physiotherapy from Jammu College of Physiotherapy in India.